FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Psychiatric Drug Consumption Among Multiple Sclerosis Patients Before and After Disability Pension; a Controlled Register Study: STUDY

























Image source: ALCOHOL.ORG

Introduction:
Many multiple sclerosis (MS) patients suffer from psychiatric comorbidity, and 60% of patients of working age are on disability pension (DP). It is unknown how transition to DP affects MS patients’ mental health.

Objectives:
To investigate the risk for being prescribed psychiatric drugs before and after receiving full-time DP in MS patients compared to matched controls.

Aims:
To examine the impact of transition of DP on MS patients' mental health.

Methods:
Nationwide Swedish registers were used to identify all 3836 MS patients who were granted full-time DP in 2000-2012, along with 19,180 propensity matched controls also being granted DP in the same years. Patients and controls were organized into cohorts by year of DP, and adjusted odds ratios (ORs) with 95% confidence intervals (95%CIs) were calculated for being prescribed Selective Serotonine Reuptake Inhibitors (SSRIs), benzodiazepines and sleeping agents in 2006.

Results:
The risk for being prescribed psychiatric drugs increased in the years leading up to DP among both MS patients and controls. After DP, the risk for benzodiazepines increased among MS patients but was unchanged among controls (OR 1.72, 95%CI 1.16-2.57). MS patients had an increased risk for SSRIs after DP compared to controls (OR 1.76, 95%CI 1.44-2.15).

Conclusions:
The risk for being prescribed psychiatric drugs after DP differs substantially between MS patients and other DP diagnoses. Possible reasons for the increased psychiatric illness among MS patients during and after transition to DP should be further investigated, as well as the role of DP as a rehabilitory measure.


Story Source: The above story is based on materials provided by SCIENCEDIRECT
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News